Clinical trials: Chronic Obstructive Pulmonary Diseases
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01696058
- Testing
- Tiotropium, Olodaterol
- Where
- 94 sites in United States
- Volunteers
- 1,137 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in…
- Trial name
- NCT01964352
- Testing
- tiotropium, olodaterol
- Where
- 77 sites in United States, Belgium and 8 more
- Volunteers
- 813 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064415
- Testing
- arformoterol, Salmeterol
- Where
- 90 sites in United States
- Volunteers
- 799 people
- Sponsor
- Sumitomo Pharma America, Inc.
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany
This investigation is designed to evaluate the performance, comfort and ease of use of the Simplus and Eson masks amongst NIV patients who are currently on Bi-level therapy
- Conditions
- Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease
- Trial name
- NCT02726048
- Testing
- Simplus/Eson
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Pulmonary Disease, Chronic Obstructive
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study.
- Trial name
- NCT01868009
- Testing
- ELLIPTA, DISKUS
- Where
- 17 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Anemia, Kidney Disease, Chronic
A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01379963
- Where
- 17 sites in Greece
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
- Trial name
- NCT01533935
- Testing
- Tiotropium + Olodaterol, Tiotropium, Olodaterol
- Where
- 33 sites in United States, Argentina and 6 more
- Volunteers
- 291 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft-versus-host-disease
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
The purpose of this study is to evaluate efficacy of SCM-CGH in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial…
- Trial name
- NCT04189432
- Testing
- SCM-CGH
- Where
- 11 sites in South Korea
- Volunteers
- 84 people
- Sponsor
- SCM Lifescience Co., LTD.
Chronic Spontaneous Urticaria
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
- Trial name
- NCT02477332
- Testing
- QGE031, Omalizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.
- Trial name
- NCT00656006
- Testing
- Albuferon, Ribavirin
- Where
- 6 sites in Canada
- Volunteers
- 43 people
- Sponsor
- Human Genome Sciences Inc.
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Pulmonary Disease, Chronic Obstructive
Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)
Study to evaluate the pharmacokinetics of tiotropium following 14 days of administration (18µg once per day) in elderly COPD patients.
- Trial name
- NCT02172326
- Testing
- Tiotropium inhalation capsules for oral inhalation
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program
This trial hopes to demonstrate the effect of 4 weeks of outpatient exercise rehabilitation on COPD patients. In particular the effect on: the amount of daily physical activity Quality of life The 6-minute walk distance Time to…
- Trial name
- NCT02100709
- Testing
- BiLevel Noninvasive Ventilation
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients
To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings
- Trial name
- NCT02172352
- Testing
- Ba 679 BR low dose, Ba 679 BR middle dose, Ba 679 BR high dose
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive…
- Trial name
- NCT02249247
- Testing
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 577 people
- Sponsor
- Boehringer Ingelheim
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
The purpose of this study is to prospectively evaluate the safety and efficacy of the AeriSeal System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.
- Trial name
- NCT01908933
- Testing
- AeriSeal Emphysematous Lung Sealant Syst
- Sponsor
- Aeris Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.